CSRP2 and breast cancer: Kaplan-Meier and logrank tests revealed that, within the basal-like subtype, breast cancer patients with higher expression of CSRP2 in the primary tumor exhibit significantly reduced metastasis-free survival as compared to patients with lower expression of CSRP2 (Figure 1A; HR = 1.98, P = 0.01).